Trials / Terminated
TerminatedNCT01155063
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 89 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.
Detailed description
This study was terminated on 01-Aug-2011 due to very low potential to enroll planned number of patients or any sufficient number of patients for complete statistical analyses. This study is not being terminated because of safety or efficacy concerns.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Aromasin (exemestane) | Aromasin (exemestane), tablets 25 mg, once a day |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-07-01
- Last updated
- 2012-10-01
- Results posted
- 2012-09-20
Source: ClinicalTrials.gov record NCT01155063. Inclusion in this directory is not an endorsement.